Tell us about your search experience on the TGA website - complete our short survey
TGA provisionally approves two oral COVID-19 treatments, molnupiravir (LAGEVRIO) and nirmatrelvir + ritonavir (PAXLOVID)
The TGA has granted provisional approval to two oral COVID-19 treatments.
Published
Related content
- TGA grants provisional approval to Gilead Sciences Pty Ltd to extend the use of the COVID-19 treatment, VEKLURY (remdesivir)The TGA has granted provisional approval to Gilead Sciences Pty Ltd to extend the use of the COVID-19 treatment, VEKLURY (remdesivir).
- TGA provisionally approves GlaxoSmithKline's COVID-19 treatment: sotrovimab (XEVUDY)On 20 August 2021 the TGA granted provisional approval to GlaxoSmithKline Australia Pty Ltd in relation to sotrovimab (XEVUDY).
- TGA grants provisional determination to Merck Sharp & Dohme's antiviral COVID-19 treatment MolnupiravirOn 9 August 2021 the TGA granted provisional determination to Merck Sharp & Dohme (Australia) Pty Ltd (MSD) in relation to Molnupiravir.